Table 5.
Determination of the studied drugs in pharmaceutical dosage forms by the proposed HPLC–DAD method and application of standard addition technique
| Pharmaceutical Formulation | CT | DSA | ||||
|---|---|---|---|---|---|---|
| Found (ng/mL) | Standard added a (ng/mL) | %R of standard added b | Found (ng/mL) | Standard added a (ng/mL) | %R of standard added b | |
| Exforge HCT® | 1.07 | 25.0 (0.05%) | 98.61 | 0.08 | 25.0 (0.05%) | 101.01 |
| Tablets | 50.0 (0.1%) | 101.04 | 50.0 (0.1%) | 100.02 | ||
| (Labeled to contain HCT 25.0 mg, VAL 160.0 mg and AML 10.0 mg) | 100.0 (0.2%) | 99.83 | 100.0 (0.2%) | 100.20 | ||
| B.N. (A518682) | Mean ± SD | 99.83 ± 1.21 | Mean ± SD | 100.41 ± 0.53 | ||
| Atenoretic® | 0.64 | 25.0 (0.05%) | 100.94 | 1.47 | 25.0 (0.05%) | 100.37 |
| capsules | 50.0 (0.1%) | 99.30 | 50.0 (0.1%) | 100.17 | ||
| (Labeled to contain HCT 25.0 mg, ATN 50.0 mg and AMI 2.5 mg) | 100.0 (0.2%) | 100.12 | 100.0 (0.2%) | 100.08 | ||
| B.N. (71047) | Mean ± SD | 100.12 ± 0.82 | Mean ± SD | 100.21 ± 0.15 | ||
| Atacand Plus® | 1.03 | 25.0 (0.05%) | 101.56 | 0.05 | 25.0 (0.05%) | 99.88 |
| Tablets | 50.0 (0.1%) | 98.83 | 50.0 (0.1%) | 100.10 | ||
| (Labeled to contain HCT 12.5 mg and CAN 16.0) | 100.0 (0.2%) | 100.19 | 100.0 (0.2%) | 99.99 | ||
| B.N. (19015) | Mean ± SD | 100.19 ± 1.36 | Mean ± SD | 99.99 ± 0.11 | ||
a Percentage w/w from HCT in a tablet
b Average of three determinations